Compare PSQH & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSQH | GRML |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 29.2M |
| IPO Year | 2021 | 2022 |
| Metric | PSQH | GRML |
|---|---|---|
| Price | $4.33 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 135.2K | ★ 7.3M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,685,987.00 | N/A |
| Revenue This Year | $80.20 | N/A |
| Revenue Next Year | $34.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1096.61 | N/A |
| 52 Week Low | $0.36 | $0.16 |
| 52 Week High | $6.36 | $0.55 |
| Indicator | PSQH | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 64.83 | 47.19 |
| Support Level | $0.61 | $0.17 |
| Resistance Level | $5.05 | $0.30 |
| Average True Range (ATR) | 0.71 | 0.02 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 66.67 | 52.61 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.